Sign In

Richard Chin

Founder and CEO of KindredBio

Professional Background

Richard Chin is a prominent figure in the biotechnology and medical research fields, known for his remarkable leadership and innovative contributions. As the Founder and Chief Executive Officer of KindredBio (NASDAQ), a groundbreaking biotechnology company focused on developing medicines specifically for pets, he demonstrates a unique blend of entrepreneurial spirit and scientific acumen. Under his guidance, KindredBio has made significant strides in advancing veterinary medicine, ensuring that pets receive the high-quality care they deserve.

Prior to his role at KindredBio, Richard made significant contributions in numerous high-profile positions. He served as the Chief Executive Officer of OneWorld Health, a nonprofit organization supported by the Gates Foundation, which was dedicated to developing affordable drugs for impoverished patients in developing countries. His commitment to global health is notable where he strived to address the urgent medical needs of underserved communities.

Moreover, Richard's impressive career includes a tenure at Genentech, a leader in biotechnology research, where he held various roles including Head of Clinical Research in both the Biotherapeutics Unit and the Cardiovascular Group. During his time at Genentech, he was instrumental in overseeing the development of multiple blockbuster drugs, contributing to the company’s reputation for innovative therapies.

Education and Achievements

Richard's academic background is equally impressive, having earned an M.D. from the esteemed Harvard Medical School, where he honed his medical expertise. Further proving his diverse skill set, he acquired an M.A. in Law from Oxford University, showcasing his commitment to understanding the intersecting worlds of science, medicine, and law. Additionally, he holds an A.B. from Harvard University.

His educational accomplishments are complemented by his distinction as a Rhodes Scholar, a title awarded to individuals who demonstrate exceptional academic achievement and leadership. This achievement exemplifies Richard’s dedication to academic excellence and his passion for applying his knowledge to make a positive impact in the world.

Richard Chin has been recognized by Businessweek as one of the 99 youngest public company CEOs in America, further establishing his reputation as a young leader in the biotechnology sector. As an author of several textbooks, he has significantly contributed to the literature on clinical practices and biomedicine, demonstrating his commitment to education and knowledge sharing in the field.

Notable Achievements

Throughout his illustrious career, Richard has been responsible for the development and oversight of numerous Investigational New Drug applications (INDs) and has played a crucial role in the registration of various New Drug Applications (NDA), Biologics License Applications (BLA), and Marketing Authorization Applications (MAA). The aggregate sales of the drugs he has worked on amount to well over $10 billion per year, underlining the profound impact he has had on the pharmaceutical industry.

Some of the notable drugs he has overseen include:

  • Lucentis: A treatment for retinal disorders.
  • Tysabri: A medication used for multiple sclerosis and Crohn’s disease.
  • Xolair: An innovative treatment for asthma and chronic hives.
  • Ocrevus: A groundbreaking therapy for multiple sclerosis.
  • Rituxan: Used for treating immunologic diseases, including certain cancers.
  • Cathflo, Prialt, TNKase, Protropin, Pulmozyme: These are just a few examples of the life-saving and life-enhancing medications that Richard has had a hand in either overseeing or developing, emphasizing his pivotal role in the biopharmaceutical landscape.

Richard's career embodies the mission of combining scientific excellence with humanitarian efforts, as demonstrated through both his work at KindredBio and his previous positions. His blend of extensive clinical knowledge, leadership expertise, and strategic vision continually positions him as a significant contributor within the fields of biotechnology and global health.

Richard Chin's successful career and dedication to advancing medical science exemplify the potential of innovative thinking combined with compassion toward both human and animal health. His enduring commitment to developing drugs for underserved populations and his leadership in the pet medicine space underscore an inspiring trajectory that benefits both initiatives globally and individual pets locally.

Related Questions

How did Richard Chin's education at Harvard Medical School and Oxford University shape his approach to biotechnology?
What inspired Richard Chin to focus on developing medicines for pets through KindredBio?
In what ways did Richard Chin's leadership at OneWorld Health impact global health initiatives?
What are some of the key strategies that Richard Chin has employed in his role as CEO of KindredBio?
How has Richard Chin contributed to the development of blockbuster drugs during his tenure at Genentech?
What are the future goals of KindredBio under Richard Chin's leadership, particularly in the field of veterinary medicine?
Richard Chin
Add to my network

Location

San Francisco, California